A BILL FOR AN ACT

RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

1 SECTION 1. Section 329-14, Hawaii Revised Statutes, is

2 amended as follows:

3	1.	By	amending	subsection	(d)	to	read:
---	----	----	----------	------------	-----	----	-------

"(d) [Any] Hallucinogenic substances. Unless specifically
excepted or unless listed in another schedule, any material,
compound, mixture, or preparation that contains any quantity of
the following hallucinogenic substances, <u>including</u> their salts,
isomers, and salts of isomers, [unless specifically excepted,]
whenever the existence of these salts, isomers, and salts of
isomers is possible within the specific chemical designation:

11 (1) Alpha-ethyltryptamine (AET);

12 (2) 2,5-dimethoxy-4-ethylamphetamine (DOET);

13 (3) 2,5-dimethoxyamphetamine (2,5-DMA);

14 (4) 3,4-methylenedioxy amphetamine;

15 (5) 3,4-methylenedioxymethamphetamine (MDMA);

16 (6) N-hydroxy-3,4-methylenedioxyamphetamine (N-hydroxy-17 MDA);



H.B. NO. ¹⁰⁹⁷ H.D. 2 S.D. 1

1	(7)	3,4-methylenedioxy-N-ethylamphetamine (MDE);
2	(8)	5-methoxy-3,4-methylenedioxy-amphetamine;
3	(9)	4-bromo-2,5-dimethoxy-amphetamine (4-bromo-2,5-DMA);
4	(10)	4-Bromo-2,5-dimethoxyphenethylamine (Nexus);
5	(11)	3,4,5-trimethoxy amphetamine;
6	(12)	Bufotenine;
7	(13)	4-methoxyamphetamine (PMA);
8	(14)	Diethyltryptamine;
9	(15)	Dimethyltryptamine;
10	(16)	4-methyl-2,5-dimethoxy-amphetamine;
11	(17)	Gamma hydroxybutyrate (GHB) (some other names include
12		gamma hydroxybutyric acid; 4-hydroxybutyrate; 4-
13		hydroxybutanoic acid; sodium oxybate; sodium
14		oxybutyrate);
15	(18)	Ibogaine;
16	(19)	Lysergic acid diethylamide;
17	(20)	Marijuana;
18	(21)	Parahexyl;
19	(22)	Mescaline;
20	(23)	Peyote;
21	(24)	N-othul-2-piperidul benzilate.

21 (24) N-ethyl-3-piperidyl benzilate;

2023-2323 HB1097 SD1 SMA.docx

1	(25)	N-methyl-3-piperidyl benzilate;
2	(26)	Psilocybin;
3	(27)	Psilocyn;
4	(28)	1-[1-(2-Thienyl) cyclohexyl] Pyrrolidine (TCPy);
5	(29)	Ethylamine analog of phencyclidine (PCE);
6	(30)	Pyrrolidine analog of phencyclidine (PCPy, PHP);
7	(31)	Thiophene analog of phencyclidine (TPCP; TCP);
8	(32)	Gamma-butyrolactone, including butyrolactone;
9		butyrolactone gamma; 4-butyrolactone; 2(3H)-furanone
10		<pre>dihydro; dihydro-2(3H)furanone; tetrahydro-2-furanone;</pre>
11		1,2-butanolide; 1,4-butanolide; 4-butanolide; gamma-
12		hydroxybutyric acid lactone; 3-hydroxybutyric acid
13		lactone and 4-hydroxybutanoic acid lactone with
14		Chemical Abstract Service number 96-48-0 when any such
15		substance is intended for human ingestion;
16	(33)	1,4 butanediol, including butanediol; butane-1,4-diol;
17		1,4- butylenes glycol; butylene glycol; 1,4-
18		dihydroxybutane; 1,4- tetramethylene glycol;
19		tetramethylene glycol; tetramethylene 1,4- diol with
20		Chemical Abstract Service number 110-63-4 when any
21		such substance is intended for human ingestion;





1	(34)	2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7),
2		its optical isomers, salts, and salts of isomers;
3	(35)	N-benzylpiperazine (BZP; 1-benzylpiperazine), its
4		optical isomers, salts, and salts of isomers;
5	(36)	1-(3-trifluoromethylphenyl)piperazine (TFMPP), its
6		optical isomers, salts, and salts of isomers;
7	(37)	Alpha-methyltryptamine (AMT)[, its isomers, salts, and
8		<pre>salts of isomers];</pre>
9	(38)	5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT)[, its
10		<pre>isomers, salts, and salts of isomers];</pre>
11	(39)	Salvia divinorum;
12	(40)	Salvinorin A;
13	(41)	Divinorin A;
14	(42)	5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DIPT) (some
15		trade or other names: 5-methoxy-3-[2-
16		(dimethylamino)ethyl]indole; 5-MeO-DMT);
17	(43)	2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);
18	(44)	2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);
19	(45)	2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);
20	(46)	2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);

2023-2323 HB1097 SD1 SMA.docx

1	(47)	2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-
2		2);
3	(48)	2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine
4		(2C-T-4);
5	(49)	2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
6	(50)	2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);
7	(51)	2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);
8	(52)	2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-
9		methoxybenzyl)ethanamine, its optical, positional, and
10		geometric isomers, salts, and salts of isomers (Other
11		<pre>names: 25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5);</pre>
12	(53)	2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-
13		methoxybenzyl)ethanamine, its optical, positional, and
14		geometric isomers, salts, and salts of isomers (Other
15		names: 25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82); [and]
16	(54)	2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-
17		methoxybenzyl)ethanamine, its optical, positional, and
18		geometric isomers, salts, and salts of isomers (Other
19		names: 25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36)[+];
20	(55)	N-ethylhexedrone, its optical, positional, and
21		geometric isomers, salts, and salts of isomers (Other



1		names: [alpha]-ethylaminohexanophenone; 2-
2		(ethylamino)-1-phenylhexan-1-one);
3	(56)	Alpha-pyrrolidinohexanophenone, its optical,
4		positional, and geometric isomers, salts, and salts of
5		isomers (Other names: [alpha]-PHP; [alpha]-
6		pyrrolidinohexanophenone; 1-phenyl-2-(pyrrolidin-1-
7		<pre>yl)hexan-1-one);</pre>
8	(57)	4-methyl-alpha-ethylaminopentiophenone, its optical,
9		positional, and geometric isomers, salts, and salts of
10		isomers (Other names: 4-MEAP; 2-(ethylamino)-1-(4-
11		<pre>methylphenyl)pentan-1-one);</pre>
12	(58)	4'-methyl-alpha-pyrrolidinohexiophenone, its optical,
13		positional, and geometric isomers, salts, and salts of
14		isomers (Other names: MPHP; 4'-methyl-alpha-
15		pyrrolidinohexanophenone; 1-(4-methylphenyl)-2-
16		(pyrrolidin-1-yl)hexan-1-one);
17	(59)	Alpha-pyrrolidinoheptaphenone, its optical,
18		positional, and geometric isomers, salts, and salts of
19		isomers (Other names: PV8; 1-phenyl-2-(pyrrolidin-1-
20		<pre>yl)heptan-1-one);</pre>

2023-2323 HB1097 SD1 SMA.docx

H.B. NO. ¹⁰⁹⁷ H.D. 2 S.D. 1

1	(60)	4'-chloro-alpha-pyrrolidinovalerophenone, its optical,
2		positional, and geometric isomers, salts, and salts of
3		isomers (Other names: 4-chloro-[alpha]-PVP; 4'-
4		chloro-[alpha]-pyrrolidinopentiophenone; 1-(4-
5		chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one); and
6	(61)	2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one
7		(methoxetamine, MXE)."
8	2.	By amending subsection (g) to read:
9	" (g)	[Any] Cannabinoids. Unless specifically excepted or
10	unless li	sted in another schedule, any of the following
11	cannabino	ids, <u>including</u> their salts, isomers, and salts of
12	isomers,	[unless specifically excepted,] whenever the existence
13	of these	salts, isomers, and salts of isomers is possible within
14	the speci	fic chemical designation:
15	(1)	Tetrahydrocannabinols; meaning tetrahydrocannabinols
16		naturally contained in a plant of the genus Cannabis
17		(cannabis plant), as well as synthetic equivalents of
18		the substances contained in the plant, or in the
19		resinous extractives of Cannabis, sp. or synthetic
20		substances, derivatives, and their isomers with
21		similar chemical structure and pharmacological





1		activity to those substances contained in the plant,
2		such as the following: Delta 1 cis or trans
3		tetrahydrocannabinol, and their optical isomers; Delta
4		6 cis or trans tetrahydrocannabinol, and their optical
5		isomers; and Delta 3,4 cis or trans-
6		tetrahydrocannabinol, and its optical isomers (since
7		nomenclature of these substances is not
8		internationally standardized, compounds of these
9		structures, regardless of numerical designation of
10		atomic positions, are covered);
11	(2)	Naphthoylindoles; meaning any compound containing a 3-
12		(1-naphthoyl) indole structure with substitution at the
13		nitrogen atom of the indole ring by a alkyl,
14		haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
15		1-(N-methyl-2-piperidinyl)methyl or 2-(4-
16		morpholinyl)ethyl group, whether or not further
17		substituted in the indole ring to any extent and
18		whether or not substituted in the naphthyl ring to any
19		extent;
20	(3)	Naphthylmethylindoles; meaning any compound containing
21		a 1H-indol-3-yl-(1-naphthyl) methane structure with



1		substitution at the nitrogen atom of the indole ring
2		by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
3		cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or
4		2-(4-morpholinyl) ethyl group whether or not further
5		substituted in the indole ring to any extent and
6		whether or not substituted in the naphthyl ring to any
7		extent;
8	(4)	Naphthoylpyrroles; meaning any compound containing a
9		3-(1-naphthoyl)pyrrole structure with substitution at
10		the nitrogen atom of the pyrrole ring by a alkyl,
11		haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
12		1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)
13		ethyl group whether or not further substituted in the
14		pyrrole ring to any extent, whether or not substituted
15		in the naphthyl ring to any extent;
16	(5)	Naphthylmethylindenes; meaning any compound containing
17		a naphthylideneindene structure with substitution at
18		the 3-position of the indene ring by a alkyl,
19		haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
20		1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
21		ethyl group whether or not further substituted in the



H.B. NO. ¹⁰⁹⁷ H.D. 2 S.D. 1

1 indene ring to any extent, whether or not substituted 2 in the naphthyl ring to any extent; 3 (6) Phenylacetylindoles; meaning any compound containing a 3-phenylacetylindole structure with substitution at 4 5 the nitrogen atom of the indole ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 6 7 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl) 8 ethyl group whether or not further substituted in the 9 indole ring to any extent, whether or not substituted 10 in the phenyl ring to any extent; (7) Cyclohexylphenols; meaning any compound containing a 11 2-(3-hydroxycyclohexyl) phenol structure with 12 13 substitution at the 5-position of the phenolic ring by 14 a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 15 cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or 16 2-(4-morpholinyl) ethyl group whether or not 17 substituted in the cyclohexyl ring to any extent; 18 Benzoylindoles; meaning any compound containing a 3-(8) 19 (benzoyl) indole structure with substitution at the 20 nitrogen atom of the indole ring by a alkyl, 21 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,



1		1-(N-methyl-2-piperidinyl) methyl, or 2-(4-
2		morpholinyl) ethyl group whether or not further
3		substituted in the indole ring to any extent and
4		whether or not substituted in the phenyl ring to any
5		extent;
6	(9)	[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)
7		pyrrolo[1,2,3-de]-1, 4-benzoxazin-6-yl]-1-
8		naphthalenylmethanone (another trade name is WIN
9		55,212-2);
10	(10)	(6a,10a)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-
11		methyloctan-2-yl)-6a,7,10,10a-
12		tetrahydrobenzo[c]chromen-1-ol (Other trade names are:
13		HU-210/HU-211);
14	(11)	Tetramethylcyclopropanoylindoles; meaning any compound
15		containing a 3-tetramethylcyclopropanoylindole
16		structure with substitution at the nitrogen atom of
17		the indole ring by an alkyl, haloalkyl, cyanoalkyl,
18		alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-
19		<pre>methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl,</pre>
20		1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
21		morpholinyl)methyl, or tetrahydropyranylmethyl group,

2023-2323 HB1097 SD1 SMA.docx

1		whether or not further substituted in the indole ring
2		to any extent and whether or not substituted in the
3		tetramethylcyclopropyl ring to any extent;
4	(12)	N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide,
5		its optical, positional, and geometric isomers, salts,
6		and salts of isomers (Other names: APINACA, AKB48);
7	(13)	Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate, its
8		optical, positional, and geometric isomers, salts, and
9		salts of isomers (Other names: PB-22; QUPIC);
10	(14)	Quinolin-8-yl 1-(5fluoropentyl)-1H-indole-3-
11		carboxylate, its optical, positional, and geometric
12		isomers, salts, and salts of isomers (Other names: 5-
13		fluoro-PB-22; 5F-PB-22);
14	(15)	N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-
15		fluorobenzyl)-1H-indazole-3-carboxamide, its optical,
16		positional, and geometric isomers, salts, and salts of
17		isomers (Other names: AB-FUBINACA);
18	(16)	N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-
19		indazole-3-carboxamide, its optical, positional, and
20		geometric isomers, salts, and salts of isomers (Other
21		names: ADB-PINACA);



H.B. NO. ¹⁰⁹⁷ H.D. 2 S.D. 1

(17)	N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-
	(cyclohexylmethyl)-1H-indazole-3-carboxamide, its
	optical, positional, and geometric isomers, salts, and
	salts of isomers (Other names: AB-CHMINACA);
(18)	N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-
	indazole-3-carboxamide, and geometric isomers, salts,
	and salts of isomers (Other names: AB-PINACA);
(19)	[1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-
	yl)methanone, and geometric isomers, salts, and salts
	of isomers (Other names: THJ-2201);
(20)	Methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-
	valinate, and geometric isomers, salts, and salts of
	isomers (Other names: FUB-AMB, Methyl 2-(1-(4-
	fluorobenzyl)-1H-indazole-3-carboxamido)-3-
	<pre>methylbutanoate, MMB-FUBINACA, AMB-FUBINACA);</pre>
(21)	(S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-
	carboxamido)-3-methylbutanoate, and geometric isomers,
	salts, and salts of isomers (Other names: 5-fluoro-
	AMB, 5-fluoro-AMP);
(22)	N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-
	indazole-3-carboxamide, and geometric isomers, salts,
	(18) (19) (20) (21)



1		and salts of isomers (Other names: AKB48 N-(5-
2		fluoropentyl) analog, 5F-AKB48, APINACA 5-fluoropentyl
3		analog, 5F-APINACA);
4	(23)	N-adamantyl-1-fluoropentylindole-3-Carboxamide, and
5		geometric isomers, salts, and salts of isomers (Other
6		<pre>names: STS-135, 5F-APICA; 5-fluoro-APICA);</pre>
7	(24)	Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-
8		carboxylate, and geometric isomers, salts, and salts
9		of isomers (Other names: NM2201; CBL2201);
10	(25)	N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-
11		(cyclohexylmethyl)-1H-indazole-3-carboxamide, and
12		geometric isomers, salts, and salts of isomers (Other
13		names: MAB-CHMINACA and ADB-CHMINACA);
14	(26)	Methyl 2-[1-(5-fluoropentyl)-1H-indazole-3-
15		carboxamido]-3,3-dimethylbutanoate (Other names: 5F-
16		ADB, [5-flouro-ADB,] <u>5-fluoro-ADB,</u> and 5F-MDMB-
17		PINACA), its optical, positional, and geometric
18		isomers, salts, and salts of isomers;
19	(27)	1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-
20		3-carboxamide, its optical, positional, and geometric
21		isomers, salts, and salts of isomers (Other names:

2023-2323 HB1097 SD1 SMA.docx

1		SGT-78; 4-CN-CUMYL BINACA; 4-CN-CUMYL-BUTINACA; CUMYL-
2		CB-PINACA; CUMYL-CYBINACA; 4-cyano-CUMYL-BUTINACA;
3		CUMYL-4CN-BINACA);
4	(28)	N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-
5		fluoropentyl)-1H-indazole-3-carboxamide (Other name:
6		5F-AB-PINACA);
7	(29)	Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-
8		carboxamido)-3-methylbutanoate (Other names: MMB-
9		CHMICA; AMB-CHMICA);
10	(30)	1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-
11		pyrrolo[2,3-b]pyridine-3-carboxamide (Other names: 5F-
12		CUMYL-P7AICA); [and]
13	(31)	Methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-
14		3-carboxamido)butanoate (MDMB-4en-PINACA)[+];
15	(32)	Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-
16		carboxamido)-3,3-dimethylbutanoate (Other name: 5F-
17		EDMB-PINACA);
18	(33)	Methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-
19		3,3-dimethylbutanoate (Other names: 5F-MDMB-PICA; 5F-
20		MDMB-2201);

2023-2323 HB1097 SD1 SMA.docx

H.B. NO. ¹⁰⁹⁷ H.D. 2 S.D. 1

1	(34)	N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-
2		carboxamide (Other names: FUB-AKB48; FUB-APINACA;
3		AKB48 N-(4-FLUOROBENZYL));
4	(35)	1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-
5		indazole-3-carboxamide (Other names: 5F-CUMYL-PINACA;
6		SGT-25); and
7	(36)	(1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-
8		tetramethylcyclopropyl)methanone (Other name: FUB-
9		<u>144).</u> "
10	SECT	ION 2. Section 329-20, Hawaii Revised Statutes, is
11	amended by	y amending subsection (b) to read as follows:
12	"(b)	Depressants. [Any] Unless specifically excepted or
13	unless li	sted in another schedule, any material, compound,
14	mixture,	or preparation [which] <u>that</u> contains any quantity of
15	the follo	wing substances, including its salts, isomers, esters,
16	ethers, a	nd salts of isomers, whenever the existence of these
17	isomers, e	esters, ethers, and salts is possible within the
18	specific (chemical designation, that has a degree of danger or
19	probable (danger associated with a depressant effect on the
20	central ne	ervous system:
21	(1)	N] man and] on t

21 (1) Alprazolam;



1	(2)	Barbital;
2	(3)	Brexanolone;
3	(4)	Bromazepam;
4	(5)	Butorphanol;
5	(6)	Camazepam;
6	(7)	Carisoprodol;
7	(8)	Chloral betaine;
8	(9)	Chloral hydrate;
9	(10)	Chlordiazepoxide;
10	(11)	Clobazam;
11	(12)	Clonazepam;
12	(13)	Clorazepate;
13	(14)	Clotiazepam;
14	(15)	Cloxazolam;
15	(16)	Daridorexant;
16	[(16)]	(17) Delorazepam;
17	[(17)]	(18) Diazepam;
18	[(18)]	(19) Dichloralphenazone (Midrin);
19	[(19)]	(20) Estazolam;
20	[(20)]	(21) Ethchlorvynol;
21	[(21)]	(22) Ethinamate;



- 1 [(22)] (23) Ethyl loflazepate;
- 2 [(23)] (24) Fludiazepam;
- 3 [(24)] (25) Flunitrazepam;
- 4 [(25)] (26) Flurazepam;
- 5 [(26)] (27) Fospropofol (Lusedra);
- 6 [(27)] <u>(28)</u> Halazepam;
- 7 [(28)] (29) Haloxazolam;
- 8 [(29)] (30) Ketazolam;
- 9 [(30)] (31) Lemborexant ((1R,2S)-2-[(2,4-dimethylpyrimidin-
- 10 5-yl)oxymethyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-
- 11 2-yl)cyclopropane-1-carboxamide);
- 12 [(31)] (32) Loprazolam;
- 13 [(32)] (33) Lorazepam;
- 14 [-(33)-] (34) Lormetazepam;
- 15 [<u>(34)</u>] <u>(35)</u> Mebutamate;
- 16 [(35)] <u>(36)</u> Medazepam;
- 17 [<u>(36)</u>] <u>(37)</u> Meprobamate;
- 18 [(37)] <u>(38)</u> Methohexital;
- **19** [(38)] (39) Methylphenobarbital (mephorbarbital);
- 20 [(39)] (40) Midazolam;
- 21 [(40)] (41) Nimetazepam;



1	[(41)] <u>(4</u>	2)	Nitrazepam;
2	[(42)] <u>(4</u>	3)	Nordiazepam;
3	[(43)] <u>(4</u>	4)	Oxazepam;
4	[(44)] <u>(4</u>	5)	Oxazolam;
5	[(45)] <u>(</u> 4	6)	Paraldehyde;
6	[(46)] <u>(</u> 4	7)	Petrichloral;
7	[(47)] <u>(4</u>	8)	Phenobarbital;
8	[(48)] <u>(4</u>	9)	Pinazepam;
9	[(49)] <u>(5</u>	0)	Prazepam;
10	[(50)] <u>(5</u>)	1)	Quazepam;
11	[(51)] <u>(5</u>	2)	Remimazolam;
12	[(52)] <u>(5</u>	3)	Suvorexant;
13	[(53)] <u>(5</u> 4	4)	Temazepam;
14	[(54)] <u>(5</u>	5)	Tetrazepam;
15	[(55)] <u>(5</u>	6)	Triazolam;
16	[(56)] <u>(5</u>	7)	Zaleplon;
17	[(57)] <u>(5</u>	8)	Zolpidem; and
18	[(58)] <u>(5</u>	9)	Zopiclone (Lunesta)."
19	SECTION	3.	Section 329-22, Hawaii Revised Statutes, is
20	amended by a	mend	ling subsection (d) to read as follows:

2023-2323 HB1097 SD1 SMA.docx

H.B. NO. ¹⁰⁹⁷ H.D. 2 S.D. 1

1	" (d)	Depressants. Unless specifically exempted or		
2	excluded	or unless listed in another schedule, any material,		
3	compound,	mixture, or preparation that contains any quantity of		
4	the following substances having a depressant effect on the			
5	central nervous system, including its salts, isomers, and salts			
6	of isomers:			
7	(1) Brivaracetam ((2S)-2-[(4R)-2-0x0-4-propylpyrrolidin-1			
8		yl]butanamide) (Other names: BRV; UCB-34714;		
9		Briviact) and its salts;		
10	(2)	Ganaxolone (3[alpha]-hydroxy-3[beta]-methyl-5[alpha]-		
11		pregnan-20-one);		
12	[(2)]	(3) Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-		
13		<pre>propionamide], (Vimpat);</pre>		
14	[(3)]	(4) Lasmiditan (2,4,6-trifluoro-N-(6-(1-		
15		<pre>methylpiperidine-4-carbonyl)pyridine-2-yl-benzamide);</pre>		
16		and		
17	[(4)]	(5) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic		
18		acid]."		
19	SECT	ION 4. Statutory material to be repealed is bracketed		
20	and stric	ken. New statutory material is underscored.		

2023-2323 HB1097 SD1 SMA.docx



1 SECTION 5. This Act shall take effect upon its approval.





Report Title: Uniform Controlled Substances Act

Description: Updates the Uniform Controlled Substances Act by adding substances scheduled under federal law. (SD1)

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.

